Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 35,378 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Epilepsy
Interventions: Levetiracetam; Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 1 Month to 4 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: San Diego, California • Buffalo, New York • Philadelphia, Pennsylvania + 3 more

Conditions: Oncologic Surgery, Cancer, Cancer Surgery, Hepatic Cancer, Gastric (Cardia, Body) Cancer, Biliary Tract Cancer, Pancreatic Cancer Resectable, Gynecologic Cancers, Gastrointestinal Cancers, Colorectal Cancer, Minimally Invasive Surgical Procedures
Interventions: Local Anesthesia, Laparoscopic Transversus Abdominis Plane block; Procedure
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cystic Fibrosis, Healthy
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 3 Years to 21 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Suicide Prevention
Interventions: VA BIC, Standard Care; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: White River Junction, Vermont

Conditions: Bladder Cancer
Interventions: Ethacrynic Acid; Drug
Lead sponsor: Eugene Lee, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Vitamin D Deficiency, Vitamin D Insufficiency, Healthy Volunteers
Interventions: ALPCO 25(OH) Vitamin D CLIA Kit; Device
Lead sponsor: American Laboratory Products Company; Industry
Eligibility: 22 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Salem, New Hampshire

Conditions: Prostate Cancer
Interventions: Leuprolide Acetate, Ipilimumab, Radical Prostatectomy; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Age-Related Macular Degeneration
Interventions: reduced fluence photodynamic therapy with Visudyne, Lucentis; Drug
Lead sponsor: Barnes Retina Institute; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Headache, Migraine
Interventions: Ketorolac, Prochlorperazine, Diphenhydramine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 17 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bile Duct Strictures, Common Bile Duct Stones
Interventions: ERCP with cholangioscopy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • Denver, Colorado • Tampa, Florida + 2 more

Conditions: Non Healing Diabetic Foot Ulcer
Interventions: MolecuLight i:X Imaging Device; Device
Lead sponsor: MolecuLight Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Vista, California • Lake Success, New York • Monroeville, Pennsylvania

Conditions: Healthy Subjects
Interventions: HSD-016, placebo; Drug · Other
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Aneurysm Cerebral
Interventions: Fred X Medical Device Intervention for Aneurysm Treatment with DAPT Therapy.; Device
Lead sponsor: Jacobs institute; Other
Eligibility: 22 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Autosomal Dominant Leukodystrophy
Interventions: nL-LMNB1-001; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: 51 Years to 51 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Covid19
Interventions: Observational; Other
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 14
States / cities: Los Angeles, California • Aurora, Colorado • Orlando, Florida + 7 more

Conditions: Hypertension, Pregnancy-Induced, Postpartum Preeclampsia, Hypertension; Maternal
Interventions: Blood Pressure Control Targets, Hypertension Management; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetic Peripheral Neuropathy
Interventions: Revascularization; Procedure
Lead sponsor: Diabetes and Glandular Disease Clinic; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pre-Exposure Prophylaxis, Telemedicine, Medication Adherence
Interventions: Face-to-Face PrEP Adherence Intervention Based on LifeSteps, Adherence Coaching Facilitated by Carium Adherence App; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Non-infectious Uveitis
Interventions: EYS606; Combination Product
Lead sponsor: Eyevensys; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Cleveland, Ohio • Arlington, Texas • Houston, Texas

Conditions: Myelodysplastic Syndrome, MDS
Interventions: pracinostat, Azacitidine, Decitabine; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 21
States / cities: Mobile, Alabama • Duarte, California • Los Angeles, California + 17 more

Conditions: Chemo-radiation Induced Nausea and Vomiting
Interventions: Rolapitant, Ondansetron; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pediatric Hematologic Malignancies
Interventions: Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Up to 30 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Coronary Restenosis
Interventions: SELUTION SLR 014 DEB, Standard of Care; Device
Lead sponsor: M.A. Med Alliance S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 34
States / cities: Loma Linda, California • Los Angeles, California • Torrance, California + 30 more

Conditions: Must be PRK Candidate
Interventions: Not listed
Lead sponsor: Durrie Vision; Other
Eligibility: 18 Years to 39 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery

Real-Time Assessment of Lung Structure and Function in Children and Young Adults With CF Using Electrical Impedance Tomography

Suicide Prevention After Community Care Discharge

Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection

ALPCO 25(OH) Vitamin D CLIA Kit - Fresh Versus Frozen Serum and Plasma Stability Study

Neoadjuvant Ipilimumab in Prostate Cancer

Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD

Intranasal Ketorolac Trial

Feasibility of a Single-operator Peroral Cholangiopancreatioscopy System (SpyGlass)

Comparing Wound Area Reduction of Non-healing DFUs Using MolecuLight i:X Versus Standard of Care

Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016

The TERUMO FRED X EARLY FEASIBILITY STUDY (FAST) STUDY.

Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)

Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study

Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy

Exploratory Study of the Efficacy of Standard of Care Revascularization of the Lower Extremity

mHealth Facilitated Intervention to Improve HIV Pre-Exposure Prophylaxis Adherence

A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU)

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies

SELUTION SLR™ 014 In-stent Restenosis

A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing